Home › Research › Getting a diagnosis
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease
Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA.. The New England journal of medicine, 2002-02-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background In cross-sectional studies, elevated plasma homocysteine levels have been associated with poor cognition and dementia. Studies of newly diagnosed dementia are required in order to establish whether the elevated homocysteine levels precede the onset of dementia or result from dementia-related nutritional and vitamin deficiencies. Methods A total of 1092 subjects without dementia (667 women and 425 men; mean age, 76 years) from the Framingham Study constituted our study sample. We examined the relation of the plasma total homocysteine level measured at base line and that measured eight years earlier to the risk of newly diagnosed dementia on follow-up. We used multivariable proportional-hazards regression to adjust for age, sex, apolipoprotein E genotype, vascular risk factors other than homocysteine, and plasma levels of folate and vitamins B12 and B6. Results Over a median follow-up period of eight years, dementia developed in 111 subjects, including 83 given a diagnosis of Alzheimer's disease. The multivariable-adjusted relative risk of dementia was 1.4 (95 percent confidence interval, 1.1 to 1.9) for each increase of 1 SD in the log-transformed homocysteine value either at base line or eight years earlier. The relative risk of Alzheimer's disease was 1.8 (95 percent confidence interval, 1.3 to 2.5) per increase of 1 SD at base line and 1.6 (95 percent confidence interval, 1.2 to 2.1) per increase of 1 SD eight years before base line. With a plasma homocysteine level greater than 14 micromol per liter, the risk of Alzheimer's disease nearly doubled. Conclusions An increased plasma homocysteine level is a strong, independent risk factor for the development of dementia and Alzheimer's disease.
What this study adds
Evidence grade: Low
This is a cross-sectional study of 1,092 participants. In this Framingham Study cohort, elevated plasma homocysteine levels measured at baseline and eight years earlier were associated with an increased risk of newly diagnosed dementia and Alzheimer's disease over a median follow-up of eight years. The study identifies homocysteine as a risk factor but does not test whether lowering it prevents dementia.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., et al. (2002). Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. The New England journal of medicine. https://doi.org/10.1056/nejmoa011613
Vancouver
Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. The New England journal of medicine. 2002. doi:10.1056/nejmoa011613. PMID: 11844848.
BibTeX
@article{seshadri2002-11844848,
author = {Seshadri, S. and Beiser, A. and Selhub, J. and Jacques, P. F. and Rosenberg, I. H. and D'Agostino, R. B. and Wilson, P. W. and Wolf, P. A.},
title = {{Plasma homocysteine as a risk factor for dementia and Alzheimer's disease}},
journal = {The New England journal of medicine},
year = {2002},
doi = {10.1056/nejmoa011613},
pmid = {11844848},
url = {https://doi.org/10.1056/nejmoa011613}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Background In cross-sectional studies, elevated plasma homocysteine levels have been associated with poor cognition and dementia.
- Studies of newly diagnosed dementia are required in order to establish whether the elevated homocysteine levels precede the onset of dementia or result from dementia-related nutritional and vitamin deficiencies.
- Results Over a median follow-up period of eight years, dementia developed in 111 subjects, including 83 given a diagnosis of Alzheimer's disease.
Why it matters
In this Framingham Study cohort, elevated plasma homocysteine levels measured at baseline and eight years earlier were associated with an increased risk of newly diagnosed dementia and Alzheimer's disease over a median follow-up of eight years. The study identifies homocysteine as a risk factor but does not test whether lowering it prevents dementia.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Study designcross-sectional
- Participants1,092
- Evidence strengthLow
How this study scored 69/100
Published in a top-tier journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (The New England journal of medicine) |
| Journal's citation record | 4 / 4 | New England Journal of Medicine: journal h-index 1,505 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2002 — older than 20 years, still counted |
| Sample size | 3 / 4 | 1,092 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 3,247 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 124.9 citations a year over 26 year(s) since 2002 |
| Impact for its field and year | 6 / 6 | Cited 109.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 67 other studies in this library |
| Still being cited | 3 / 4 | Cited 188 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Philip A. Wolf: h-index 149 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Boston University: institution h-index 1,456 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 11844848) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 69 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1056/nejmoa011613
- PubMed: 11844848
- Original source →
- Free full text: New England Journal of Medicine →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
67 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Getting a diagnosis from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.